This new meta-analysis looked to better solidify connections between atopic dermatitis and environmental irritants, such as ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

According to long-term safety analyses of abrocitinib in moderate-to-severe atopic dermatitis, which of the following is a notable monitoring need?

In a meta-analysis of 42 studies, exposure to air pollutants and high temperatures was associated with higher risk for clinic ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

New research published in Current Issues in Pharmacy and Medical Sciences found that a hemp seed oil-based topical emulsion ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

Early childhood atopic dermatitis does not affect executive function during middle childhood, particularly in those with mild phenotypes.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Wall Street analysts sharply upgraded their outlook on Nektar Therapeutics on Wednesday following positive topline results from the company’s Phase 2b REZOLVE-AD trial of rezpegaldesleukin in patients ...